Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for
the treatment of purulent bacterial conjunctivitis, and to assess the safety